| Bristol-Myers Squibb SA - Zeposia 0.92 mg, Hartkapseln | | 67046 | | 03 | | Zeposia 0.92 mg | | Hartkapseln | | L04AE02 | | | | 11.08.2020 | | |
| | Composition | | ozanimodum 0.92 mg ut ozanimodi hydrochloridum 1, cellulosum microcristallinum, silica colloidalis anhydrica, carmellosum natricum conexum corresp. natrium max. 0.187 mg, magnesii stearas, Kapselhülle: gelatina, E 171, E 172, Drucktinte: lacca, propylenglycolum, kalii hydroxidum, E 172, pro capsula. | | Packungsbestandteile | | Capsules | | | | | Principe actif | Concentr. |
|---|
| Ozanimodum | 0.92 mg |
| | BAG: Principe actif | Concentr. |
|---|
| Ozanimodum | 0.92 mg |
| | | | Agents auxilliaires | | informations additionels |
|---|
| Carmellosum Natricum Conexum | | | | Cellulosum Microcristallinum | | | | E 171 | | color. | | E 172 | | color. | | Gelatina | | Kapselhülle | | Kalii Hydroxidum | | | | Lacca | | Drucktinte | | Magnesii Stearas | | | | Pro Capsula | | | | Propylenglycol | | | | Silica Colloidalis Anhydrica | | |
| |
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 002 | 28 | 1175.82 | 1295.20 | B | LS | Oui |
|
|
